NCT02028156

Brief Summary

This is a non-randomized, single-group, multi-center, two phased study to evaluate formula intolerance.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 6, 2013

Completed
26 days until next milestone

Study Start

First participant enrolled

January 1, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 7, 2014

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
Last Updated

November 7, 2014

Status Verified

November 1, 2014

Enrollment Period

7 months

First QC Date

December 6, 2013

Last Update Submit

November 5, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Improvement in Fussiness

    Study phase 2; Parent completed questionnaire.

    0 to 15 days

Secondary Outcomes (4)

  • Diarrhea

    0 to 4 weeks

  • Constipation

    0 to 4 weeks

  • Spit-up

    0 to 4 weeks

  • Gassiness

    0 to 4 weeks

Study Arms (1)

Partially Hydrolyzed Infant Formula

EXPERIMENTAL

Fed ad lib.

Other: Partially Hydrolyzed Infant Formula

Interventions

Commercially available infant formula

Partially Hydrolyzed Infant Formula

Eligibility Criteria

AgeUp to 60 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Singleton full term birth with birth weight of \> 2500g.
  • Infant between 0 and 60 days of age.
  • Discontinuation of medications that might affect gastrointestinal (GI) tolerance.
  • Infant is exclusively formula-fed a full-lactose, intact cow milk protein-based infant formula (CMF) for less than 7 days prior to enrollment.
  • Infant was fed according to protocol in Stage 1 of the study.
  • Infant was identified as being fussy using the Intolerance Assessment Tool in Stage 1.

You may not qualify if:

  • Chromosomal or major congenital anomalies.
  • Suspected or known metabolic or physical diseases affecting infant feeding and/or metabolism.
  • Hospitalization, other than for delivery, prior to enrollment.
  • Severe uncontrolled eczema, visible bloody stools or milk protein allergy prior to enrollment.
  • More than 1 substitution of an infant formula other than full-lactose, intact cow milk formula (CMF) since birth.
  • Use of a prokinetic drug within 7 days before enrollment.
  • Infant's intolerance symptom was caused by another reason, for example known infection/illness, food allergy, or response to vaccination(s).
  • Infant has immunization(s) within 3 days of enrollment in Stage 2.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Guangdong Women and Children Hospital

Guangzhou, Guangdong, China

Location

Nanjing Maternity and Child Health Care Hospital

Nanjing, Jiangsu, China

Location

Xin Hua Hospital

Shanghai, China

Location

Study Officials

  • Shirley Li, MD

    Abbott Nutrition China

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2013

First Posted

January 7, 2014

Study Start

January 1, 2014

Primary Completion

August 1, 2014

Study Completion

August 1, 2014

Last Updated

November 7, 2014

Record last verified: 2014-11

Locations